A novel interferon β1-A purification technology

L. Vaca, A. Sampieri, J. Zepeda
Universidad Nacional Autónoma de México, MX

Keywords: interferon, purification, multiple sclerosis


A novel Interferon β1-A production and purification technology consists on producing Interferon B1A coupled to a nano-encapsulating protein so as to facilitate its purification. Interferon β1-A is a widely used therapeutic protein for treatment of several diseases such as multiple sclerosis (MS). Commonly used interferon synthesis platforms usually generate low yields with high purification costs. The protein is commercialized by several pharmaceutical companies and is listed among the top 10 biotech products worldwide with estimated revenues of US$2.5 billion in 2010 (5). Our technology allows the production of interferon at high yields preserving compatibility and functionality, ensuring biosafety and purity in the product Using genetic engineering tools, Interferon β1-A is produced in SF9 insect cells using a Baculovirus Expression Vector System, a versatile biotechnological tool and a suitable platform for recombinant protein manufacture in insect cell cultures providing higher yields at lower costs than mammalian cultures, while preserving protein structure and ensuring effectiveness (3). Interferon β1-A is encapsulated in crystals allowing its easy purification. Those crystals are insoluble at certain pH ranges, thus it is possible to isolate them by precipitation. Interferon is purified using a specific protease to release it from nano-crystals.